Heightened levels of circulating 20S proteasome in critically ill patients
- 9 June 2005
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 35 (6) , 399-403
- https://doi.org/10.1111/j.1365-2362.2005.01508.x
Abstract
Background Recently, circulating proteasome core particles (20S proteasome) have been suggested as a marker of cell damage and immunological activity in autoimmune diseases. Aberrant leucocyte activation and increased lymphocyte apoptosis with consecutive T‐cell unresponsiveness is deemed to play a pivotal role in the sepsis syndrome. Moreover sepsis‐induced muscle proteolysis mainly reflects ubiqutin proteasome‐dependent protein degradation. We therefore sought to investigate serum levels of 20S proteasome in critical ill patients.Material and methods Case–control‐study at a university hospital intensive care unit; 15 patients recruited within 24–48 h of diagnosis of sepsis, 13 trauma patients recruited within 24 h of admission to the ICU, a control group of 15 patients who underwent abdominal surgery, and 15 healthy volunteers. ELISA was used to measure the concentration of 20S proteasome in the sera of the patients and controls. Data are given as mean ± SEM. Mann–Whitney U‐test was used to calculate significance and a P‐value of 0·05 was considered to be statistically significant.Results Marked increase of 20S proteasome was detected in the sera of septic patients (33 551 ± 10 034 ng mL−1) as well as in trauma patients (29 669 ± 5750 ng mL−1). In contrast, significantly lower concentrations were found in the abdominal surgery group (4661 ± 1767 ng mL−1) and in the healthy control population (2157 ± 273 ng mL−1).Conclusion Detection of 20S proteasome may represent a novel marker of immunological activity and muscle degradation in sepsis and trauma patients, and may be useful in monitoring the clinical effect of proteasome‐inhibitors.Keywords
This publication has 22 references indexed in Scilit:
- Molecular mechanisms activating muscle protein degradation in chronic kidney disease and other catabolic conditionsEuropean Journal of Clinical Investigation, 2005
- Regulation of Fas (APO-1, CD95) and Fas Ligand Expression in Leukocytes During Systemic Inflammation in HumansShock, 2003
- The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling EventsThe Journal of Immunology, 2003
- Death Receptor Signaling and AutoimmunityImmunologic Research, 2003
- Sepsis-Induced Muscle Proteolysis Is Prevented by a Proteasome Inhibitor in VivoBiochemical and Biophysical Research Communications, 2000
- Lymphocyte activation after non-thermal traumaBritish Journal of Surgery, 2000
- Impaired Immunoproteasome Assembly and Immune Responses in
PA28
−/−
MiceScience, 1999
- Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle.Journal of Clinical Investigation, 1997
- Sir Isaac Newton, sepsis, SIRS, and CARSCritical Care Medicine, 1996
- A role for the proteasome regulator PA28α in antigen presentationNature, 1996